ANSWER: Denosumab (Prolia) is a treatment for osteoporosis that is normally given as an injection every six months. Among its ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

The Food and Drug Administration has approved Teva's Prolia biosimilar, and the agency is reviewing Teva's Xolair biosimilar application. “The FDA approval of Ponlimsi is a significant milestone that ...

I’m a 79-year-old female who’s in good health. I am 5 feet tall and weigh 95 pounds, and I’m very active. I’ve been taking Prolia for the past two to three years for osteoporosis, which has since ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

Boncresa is supplied as a 60 mg/mL single-dose prefilled syringe for SC injection and Oziltus is supplied as a 120 mg/1.7 mL single-dose vial for SC injection. Boncresa is approved to treat ...

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA ...

JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo), biosimilars referencing PROLIA ® (denosumab) and XGEVA ® ...